Chris Sweeney (last author) discusses the ATK inhibitor Ipatercertib in pTEN altered castrate resistant prostate cancer. A positive R3 trial in the ESMO plenary session.
The Uromigos Episode 59: Ipatercertib in Biomarker Positive Castrate Resistant Prostate Cancer
By The Uromigos - Last Updated: September 20, 2020
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.